Latest 8-K filings

Suncrete, Inc. announced a 146% year-over-year revenue increase for Q2 2026, reaching $97.2 million, while maintaining its full-year financial guidance despite a widened net loss.

Replimune Group announced FDA accelerated approval for TUDRIQEV in combination with nivolumab for advanced melanoma, alongside a $150 million financing to support commercial launch and clinical trials.

Aptevo Therapeutics announced second-quarter 2026 financial results and a business update, detailing strong clinical momentum for mipletamig in AML, a new Chief Scientific Officer, non-dilutive funding for APVO451, and a radiopharmaceutical collaboration with Niowave.

Delcath Systems, Inc. has updated its bylaws to designate exclusive forums for corporate and federal securities claims.

BIO-key International announced a 13% increase in Q2 revenues and a 51% reduction in net loss, driven by strong license fee growth and international contract wins.

Outlook Therapeutics announced third quarter fiscal year 2026 financial results and highlighted the FDA approval of LYTENAVA, positioning it for a U.S. launch with significant sales potential.

VerifyMe, Inc. announced its second quarter 2026 financial results, reporting a substantial decrease in revenue but an improvement in gross profit margin.

PDS Biotechnology Corporation stockholders approved an amendment to increase authorized common stock from 150 million to 300 million shares at the 2026 annual meeting.

PMV Pharmaceuticals announced second quarter 2026 financial results, highlighting the completion of patient enrollment for its Phase 2 PYNNACLE trial and planning a 2027 NDA submission for rezatapopt.

Aptera Motors Corp. announced the appointment of Wellington J. Reiter as an independent director, increasing the board size and adding expertise to its Audit Committee.

Galectin Therapeutics reported Q2 2026 financial results, highlighting an agreement with the FDA for its Phase 3 belapectin trial in MASH cirrhosis and a substantial debt conversion into equity.

LanzaTech Global, Inc. announced its second quarter 2026 financial results, highlighting a substantial decrease in operating expenses and an improvement in Adjusted EBITDA, alongside strategic progress in sustainable fuel certifications.

TuHURA Biosciences announced its second quarter 2026 financial results, highlighting progress in its immuno-oncology pipeline and a $50 million credit facility extending cash runway.

Edible Garden AG Incorporated announced second quarter 2026 results, showcasing 12.8% revenue growth to $3.6 million and significant progress in its Farm-to-Formula strategy, including RTD prototype completion.

Western Union's acquisition of Intermex faces a setback as California suspends its approval, despite securing New York's consent with certain commitments.

Lantern Pharma announced second quarter 2026 financial results, detailing progress in its oncology drug pipeline, including LP-300 and LP-184, and the establishment of Open Medicine AI as a separate entity.

Beneficient announced its first quarter fiscal 2027 results, featuring a new collateral management services engagement and over $16 million in primary capital commitments, alongside reduced operating expenses.

Digi Power X announced strong Q2 2026 results, highlighting first AI compute revenue, $1.1 billion in contracted future revenue, and a positive Adjusted EBITDA, while projecting a $250M-$300M annualized revenue run-rate by Q3 2027.

Sotera Health Company announced the resignation of Class I director James C. Neary, effective August 13, 2026, with the board size adjusted to eleven directors.

Neumora Therapeutics announced second quarter 2026 financial results, detailing pipeline advancements, a leadership transition with Joshua Pinto appointed CEO, and a cash runway extending into Q3 2027.

Teamshares Inc. announced robust second quarter 2026 financial results, showcasing significant year-over-year growth in revenue and Adjusted EBITDA, and reaffirmed its full-year 2026 outlook.

Tvardi Therapeutics reported second quarter 2026 results, highlighting positive healthy volunteer data for its next-generation STAT3 inhibitor TTI-109 and selecting ulcerative colitis as its initial indication, while also noting a reduced cash position.

Core Scientific has successfully acquired Polaris DS LLC for approximately $444 million in cash, significantly expanding its power infrastructure and advancing its Muskogee expansion plans.

Beyond Meat announces the effectiveness of its 1-for-30 reverse stock split and a reduction in authorized shares, aiming to regain Nasdaq compliance.

RF Acquisition Corp II has amended its trust agreement and articles of association to extend the deadline for its business combination to February 15, 2027, with associated monthly deposits into its trust account.

PowerCompute announced Q2 2026 financial results, showing a 9.8% year-over-year revenue increase to $2.1 million, alongside a strategic expansion into high-performance computing (HPC) and AI infrastructure.

Cable One, Inc. announced the appointment of Heather McCallion as Chief Operating Officer, effective August 24, 2026, to lead operational strategy and execution.

ACCO Brands Corporation announced a definitive agreement to acquire Trust, a European provider of computer and gaming accessories, for approximately $57 million.

Amcor plc announces a change in its independent registered public accounting firm, transitioning from PwC Switzerland to PwC US, effective August 14, 2026.

Lincoln International, Inc. has issued 1,433,927 shares of Class A common stock to satisfy obligations to former partners following its initial public offering.